July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Adjuvant high-dose rate (HDR) brachytherapy for ocular tumours with orbital invasion
Author Affiliations & Notes
  • Monica Maria Pagliara
    Ocular Oncology Unit, Department of Ophthalmology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Luca Tagliaferri
    Gemelli Advanced Radiation Therapy Center, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Angela Lanza
    Ocular Oncology Unit, Department of Ophthalmology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Luigi Azario
    Physics Institute, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Gustavo Savino
    Ocular Oncology Unit, Department of Ophthalmology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Rosa Autorino
    Gemelli Advanced Radiation Therapy Center, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • andrea scupola
    Ocular Oncology Unit, Department of Ophthalmology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Vincenzo Valentini
    Gemelli Advanced Radiation Therapy Center, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Maria Antonietta Blasi
    Ocular Oncology Unit, Department of Ophthalmology, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
  • Footnotes
    Commercial Relationships   Monica Pagliara, None; Luca Tagliaferri, None; Angela Lanza, None; Luigi Azario, None; Gustavo Savino, None; Rosa Autorino, None; andrea scupola, None; Vincenzo Valentini, None; Maria Antonietta Blasi, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5605. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Monica Maria Pagliara, Luca Tagliaferri, Angela Lanza, Luigi Azario, Gustavo Savino, Rosa Autorino, andrea scupola, Vincenzo Valentini, Maria Antonietta Blasi; Adjuvant high-dose rate (HDR) brachytherapy for ocular tumours with orbital invasion. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5605.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate adjuvant high-dose rate (HDR) brachytherapy effectiveness in local control, functional and cosmetic outcome in patients affected by ocular malignant tumours with orbital invasion.

Methods : A retrospective study was conducted in 9 patients affected by malignant eye cancer infiltrating the orbit , treated with surgical excision and subsequent (HDR) brachytherapy between 20012-2017. The primary tumour was uveal melanoma with extrascleral extension in 2 (22.2%) patients, conjunctival melanoma in 4 (44.4%), basal cell carcinoma in 1 (11.1%), squamous cell carcinoma in 1(11.1%) and sebaceous carcinoma in 1(11.1%).The surgical procedures consisted of modified enucleation in 4 patients (two affected by uveal melanoma with extrascleral extension and two affected by conjunctival melanoma with globe invasion) and surgical excision of the primary tumour and orbital infiltration in the remaining patients.
Within one month from the surgery each underwent adjuvant interstitial high doses brachytherapy with 192Ir. A target dose of 3400 cGy (range, 3000-3400 cGy) was delivered in 10-12 twice-daily fractions (range, 250-340 cGy per fraction) over 5-6 consecutive days. Data analysis included local tumor control and metastatic rate, side effects, functional and aesthetic results.

Results : in all patients treatment was well tolerated, there was no orbital recurrence at a median follow-up of 12,6 months (range 3-28 months). One patient died of metastatic disease. No significant side effect was observed, functional and cosmetic outcomes were optimal.

Conclusions : postoperative high-dose-rate brachytherapy resulted in an excellent disease control and cosmesis without significant acute or late side effects. It rappresents an alternative treatment to external beam radiation for eye with orbit invasion.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×